NanoMosaic and Solid Biosciences announced a comarketing agreement focused on improving AAV manufacturing analytics for gene therapy developers. NanoMosaic will promote its Tessie automated plate reader for multiplex testing of AAV vector genome and capsid titers, paired with Solid’s Polaris-101 capsid targeting skeletal muscle and cardiac tissue. The collaboration centers on the Tessie platform’s ability to measure full, partial, and empty capsids while quantifying transgene and capsid titers on the same chip—an approach intended to support safety, dosing, and efficacy decisions during CMC development. Terms of the deal were not disclosed. The announcement follows NanoMosaic’s recent FDA AMT designation for Tessie earlier this year, signaling regulatory momentum for automated manufacturing analytics tools in gene therapy.